← Back to Search

CAR T-cell Therapy

Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01)

Phase 1
Waitlist Available
Research Sponsored by Cellectis S.A.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new treatment called UCARTCS1A, which uses modified immune cells to target and kill cancer cells. It is aimed at patients with multiple myeloma that has come back or didn't respond to other treatments. The goal is to see if this treatment is safe and effective. UCARTCS1A is a type of CAR-T cell therapy, which is a promising approach in treating multiple myeloma by using modified immune cells to target cancer cells.

Eligible Conditions
  • Relapsed or Refractory Multiple Myeloma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Safety of UCARTCS1A
Secondary study objectives
Duration of Response
Overall Survival
Progression Free Survival
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Dose EscalationExperimental Treatment1 Intervention
Several tested doses of UCARTCS1A until the Maximum Tolerated Dose (MTD) is identified.

Find a Location

Who is running the clinical trial?

Cellectis S.A.Lead Sponsor
5 Previous Clinical Trials
186 Total Patients Enrolled

Media Library

UCARTCS1A (CAR T-cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT04142619 — Phase 1
Multiple Myeloma Research Study Groups: Dose Escalation
Multiple Myeloma Clinical Trial 2023: UCARTCS1A Highlights & Side Effects. Trial Name: NCT04142619 — Phase 1
UCARTCS1A (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04142619 — Phase 1
~2 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top